Ardelyx ardelyx.com


Public list: BIO 2016 (619) Smart Money VCs (6328) Pharma Startups (4743)

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has disc...Show all

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gast...Show all

Company (IPO / Went public)

Phone: 510-745-1700

Fax:

34175 Ardenwood Blvd.

Fremont, 94555
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Ardelyx $86.1M Jul 15, 2016
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Ardelyx Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors

Rimon Therapeutics

Ontario, Canada
Alive / ActiveRimon Therapeutics, through the application of its polymer chemistry platform, is developing therapeutics to address unmet needs in important disease indicators with large markets. Rimon's therapeutic polymers - trademarked Theramers - are in that they deliver therapeutic effect without incorporating or releasing drugs. Theramers are intended to be used as solids-scaffolds, microbeeds and coatings - acting locally, without systemic consequences.Login to see details

Micromet

Bethesda, Maryland, United States
AcquiredMicromet is focused on biological products for the treatment and control of cancer, inflammatory and autoimmune diseases. Using its antibody technology platforms, Micromet strives to create novel drugs that are highly specific, effective and well tolerated in patients. Its lead drug candidate is Adecatumumab (MT201), which offers a human antibody for treatment of solid tumors. In January 2012, Micromet was acquired by Amgen. The valuation of Micromet was $1.16 billion.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions and methods for treating hyperkalemia Jul 29, 2016 Mar 20, 2018 Patent
Compositions and methods for treating hyperkalemia Mar 29, 2017 Jan 16, 2018 Patent
Compositions and methods for treating hyperkalemia Dec 22, 2015 May 23, 2017 Patent
Pharmaceutical compositions for treating hyperkalemia Feb 24, 2016 Jan 24, 2017 Patent
Pharmaceutical compositions for treating hyperkalemia Feb 24, 2016 Jan 17, 2017 Patent
See all 16 patents